Armistice Capital, LLC Zymeworks Inc. Transaction History

Armistice Capital, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$4.65 - $7.43 $60,450 - $96,590	13,000 Added 0.23%	5,785,000 $35.6 Million
Q2 2022 Aug 15, 2022	BUY	$4.82 - $7.7 $57,840 - $92,400	12,000 Added 0.21%	5,772,000 $30.6 Million
Q1 2022 May 16, 2022	BUY	$6.0 - $16.98 $27.1 Million - $76.6 Million	4,509,803 Added 360.73%	5,760,000 $37.7 Million
Q4 2021 Feb 14, 2022	SELL	$15.19 - $29.33 $19.3 Million - $37.4 Million	-1,273,803 Reduced 50.47%	1,250,197 $20.5 Million
Q3 2021 Nov 15, 2021	BUY	$27.35 - $37.28 $14.3 Million - $19.5 Million	524,000 Added 26.2%	2,524,000 $73.3 Million
Q2 2021 Aug 16, 2021	BUY	$26.5 - $38.23 $9.28 Million - $13.4 Million	350,000 Added 21.21%	2,000,000 $69.4 Million
Q1 2021 May 17, 2021	BUY	$29.83 - $56.81 $35.8 Million - $68.2 Million	1,200,000 Added 266.67%	1,650,000 $52.1 Million
Q4 2020 Feb 16, 2021	SELL	$39.12 - $54.99 $10.4 Million - $14.6 Million	-266,000 Reduced 37.15%	450,000 $21.3 Million
Q3 2020 Nov 16, 2020	SELL	$29.21 - $46.58 $1.81 Million - $2.89 Million	-62,000 Reduced 7.97%	716,000 $33.4 Million
Q2 2020 Aug 14, 2020	BUY	$33.67 - $40.0 $26.2 Million - $31.1 Million	778,000 New	778,000 $28.1 Million

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $903M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Armistice Capital, LLC with notifications on news.